Dr. Chris Boyle

DR. CHRIS BOYLE is a life sciences regulatory lawyer, solicitor-advocate, and qualified veterinarian who advises pharmaceutical, biotech, MedTech, and animal health companies on UK and EU regulatory strategy, life sciences transactions, and high-stakes regulatory disputes.

“Chris is highly responsive and someone who is able to simplify complex regulations for clients.”
Chambers UK 2026

“Chris Boyle is a dual-qualified vet and lawyer. Scientific knowledge is flawless. He is very measured and his composure feeds into his clients. A game-changer.”
Legal 500 UK 2026

Pharmaceutical and Biopharmaceutical Regulatory Advice. Chris supports pharmaceutical and biopharmaceutical companies across the full product lifecycle, from development and clinical trials through to regulatory approval, market access, manufacturing, distribution, and post-marketing compliance.

He advises on Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and Good Distribution Practice (GDP) requirements, health technology assessment (HTA), pricing and reimbursement, and regulatory exclusivity strategy, including regulatory data protection, orphan and paediatric rewards, and supplementary protection certificates (SPCs).

Chris regularly advises on interactions with the MHRA, the EMA, NICE, and other regulators and health technology assessment bodies. He guides clients through the UK’s evolving medicines regulatory landscape, including the International Recognition Procedure (IRP), the Innovative Licensing and Access Pathway (ILAP), the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), and the Windsor Framework.

Contentious Regulatory, Litigation, and Enforcement Experience. Chris has a strong contentious regulatory practice and represents clients in high-stakes regulatory disputes involving medicines, medical devices, market access, and enforcement of regulatory exclusivities.

He has represented clients before the UK and EU courts, including in the landmark UK Supreme Court case Secretary of State for Health v. Servier Laboratories [2021] UKSC 24, in which an extended panel of seven Supreme Court Justices unanimously upheld Servier’s strike-out of a claim for causing loss by unlawful means in the context of damages proceedings exceeding £300 million.

Chris has also acted in multiple Court of Appeal hearings and has a successful track record in resolving contentious regulatory matters involving the EMA, MHRA, UK Home Office, NICE, and the Veterinary Medicines Directorate (VMD). He supports clients in challenging decisions of regulators and health technology assessment bodies, and in enforcing regulatory exclusivities, including SPCs and related IP-regulatory rights.

Medical Devices, MedTech, Digital Health, and AI. For MedTech, digital health, and health technology clients, Chris advises on medical device classification, certification, and post-market requirements. His work includes advising on UKCA and CE marking, the transition to the new UK medical device regulatory framework, EU Medical Device Regulation (MDR), and EU In Vitro Diagnostic Medical Devices Regulation (IVDR) compliance. Chris guides MedTech companies on post-market surveillance, vigilance, benefit-risk assessments, and interactions with MHRA. Chris is experienced in helping developers of software as a medical device (SaMD), AI as a medical device (AIaMD), and advises on borderline classification issues.

Life Sciences Transactions, M&A, and Private Equity. Chris supports life sciences M&A, corporate transactions, and private equity investments by providing specialist regulatory due diligence, risk assessment, and industry insight. He advises on regulatory issues affecting pharmaceutical, biotech, MedTech, diagnostics, contract research organisation, animal health, veterinary medicines, feed, and life sciences services businesses.

Animal Health, Veterinary Medicines and One Health. In animal health, Chris founded and chairs Sidley’s Animal Health Legal Forum, a network for animal health professionals, regulatory affairs colleagues, and investors. He coordinates Sidley’s global animal health practice and provides strategic guidance to companies across the veterinary medicines, feed, diagnostics, and veterinary services sectors.

Chris advises animal health clients on veterinary medicines regulation, animal health product development, regulatory approvals, market access, product lifecycle strategy, advertising and promotion, recalls, regulatory data protection, SPCs, diagnostics, feed, feed supplements, and issues affecting veterinary services businesses.

As a qualified veterinarian and lawyer, Chris brings scientific and industry understanding to animal health regulatory matters and advises companies adopting a One Health approach across animal health, human health, and environmental health.

Scientific Background. Chris’s scientific background enables him to work closely with legal, regulatory affairs, medical, technical, and commercial teams, translating complex regulatory frameworks into practical, business-focused advice.

Chris is ranked Band 2 in Chambers UK 2026 for Life Sciences: Regulatory and is named by Legal 500 UK 2026 for Life Sciences and Healthcare. He was also named in the inaugural 2024 Pro Bono Recognition List of England and Wales and writes and speaks regularly on UK and EU life sciences regulation.

Representative experience includes advising:

• Caidya, a leading global contract research organization, in its strategic combination with Simbec-Orion, a UK-headquartered CRO specialising in clinical pharmacology, oncology, and rare disease clinical research.
• Vivo Capital, a global investment firm focused exclusively on healthcare and life sciences, on its acquisition of Dutscher Group, a European leader in consumables and equipment distribution for R&D laboratories.
  
• GE HealthCare on the regulatory aspects of its US$2.3 billion acquisition of Intelerad, a medical imaging software company specialising in medical imaging and enterprise workflow solutions.
• Les Laboratoires Servier in UK parallel proceedings brought by health authorities in England, Wales, Scotland, and Northern Ireland seeking damages for an alleged over-spend on medicines as a result of alleged breaches of competition rules.
• KKR on its acquisition of Argenta, an animal health-focused pharmaceutical research and manufacturing company.
• Archer Daniels Midland on its acquisition of Probiotics International Limited, a UK-based provider of probiotic supplements for human, pet, and production-animal use.